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Abstract
Cell-free DNA Sequencing in Multiple Myeloma

Russell M. Irwin, BS.ASNR

Advisory Professor: Michael R. Green, PhD

Multiple myeloma (MM) is an incurable plasma cell dyscrasia. Recent advances in
MM therapy, including CAR-T therapy, have increased survival and shown the value of
assessing treatment response with great sensitivity, both in acute and long-term settings. Cellfree DNA, DNA fragments which are released into circulation as a part of normal cellular
turnover, is a useful and dynamic biomarker in cancer patients due to the presence of
circulating tumor DNA (ctDNA), which is readily identified using next generation
sequencing. Here we report the analytical sensitivity, applicability, consistency, and
prognostic ability of M5Seq, a novel hybrid capture panel designed for MM ctDNA. We
performed in-silico validation of this panel and found high applicability (1,173/1,212 tumors
with ≥1 variant covered, 97%, mode 6 variants covered). By sequencing serial dilutions of
simulated cancer DNA in healthy donor DNA, we observed a limit of analytical sensitivity at
5x10-5 and a limit of linearity at 10-4. Then, we applied this method to the matched pretreatment tumor and plasma samples of 10 newly diagnosed MM patients. We observed
moderate concordance in the mutations detected in each compartment, consistent with
existing literature. Based off these data, we applied M5Seq to plasma samples from 18
patients undergoing anti-BCMA chimeric antigen receptor T cell therapy (CAR-T). We
observed similar concordance in the CAR-T cohort as in the newly diagnosed patients. In 14
evaluable patients, we observed no statistically significant decreases in variant allele fraction
vi

within two days of CAR-T infusion between patients achieving a complete response or better
within 30 days of infusion as determined by IMWG criteria, as compared to those patients
with stable or progressing disease. Furthermore, while we observed a slight overall survival
advantage in patients with decreased VAF from baseline, this association did not meet the
threshold for statistical significance.
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6.1

Introduction
Multiple myeloma etiology, biology, and treatment
Multiple myeloma (MM) is a malignancy of differentiated, mature lymphoid-derived

plasma cells which presents most often in patients over the age of 50[1]. MM occurs at an
age-adjusted frequency of 4.3 per 100,000 in the United States, with greater frequency in
African Americans than other ethnic groups, and with greater frequency in men than
women[2]. The average age of onset for MM is 66 years[3].
MM is characterized by genetic heterogeneity, mutational burden, and high-risk
genomic lesions including t(4;14) 14q32, del(17p) and del(13q) [4-7]; hyperdiploidies
presenting as trisomies in odd-numbered chromosomes are also common. Plasma cells,
having undergone multiple rounds of somatic hypermutation and class-switch recombination,
frequently see off-target single nucleotide variants (SNVs) and indels characteristic of
cytosine deaminase activity in B cell malignancies, such as in Bcl6, Cd19, Cd83, Pax5, and
Bcl11[8, 9].
Plasma cells are characteristic in that they are antibody-secreting cells, and because
multiple myeloma tumor cells are typically derived from the same clone, they all secrete the
same antibody. This antibody is detectable via serum protein electrophoresis and
immunofixation and is used as a primary biomarker, known as the M (myeloma) protein[10].
In addition, many tumors secrete excess free light chain, disrupting the normal ratio of κ
isotype free light chains in serum to λ free light chains. The serum free light chain (sFLC)
ratio is also an important metric of performance[11].
Frontline treatment for MM is based on autologous stem cell transplant (ASCT) and
alkylating chemotherapy, bookended by combination therapies of steroids, proteasome
1

inhibitors, and immunomodulatory agents. In the last 15 years, the introduction of novel
therapeutics such as bortezomib and other proteasome checkpoint inhibitors has dramatically
improved overall survival (OS) and progression-free survival (PFS) in patients who respond
well to first-line treatments[12].
This increased survival has exposed a weakness in the traditional histopathology- and
protein-based definitions of complete response (CR) and stringent complete response (sCR),
which are now inadequate for predicting survival[13].

6.1.1 Chimeric antigen receptor T-Cell therapy
Another major development in MM therapy is the recent FDA approval of chimeric
antigen receptor T-cells (CAR-T) targeting B cell maturation antigen (BCMA), ABECMA
(idecabtagene vicleucel, ide-cel) in 2020[14] and CARVYKTI (ciltacabtagene autoleucel,
cilta-cel) in 2022. Both treatments utilize patient-derived CD8+ T-cells transfected with
vector coding for the second-generation chimeric antigen receptor construct, including a
BCMA-specific short chain variable fragment (scFv), 4-1BB costimulatory domain, and
CD3ζ signaling domain. These cells are expanded ex vivo. The patient then undergoes
lymphodepleting chemotherapy before cell reinfusion.
Results of the initial KarMMa trial of ide-cel indicate an 85% overall response rate
and a 45% complete response rate. However, within six months of infusion, 40% of complete
responders experienced a relapse, and median progression-free survival was 11.8
months[15]. Similarly, the CARTITUDE-1 trial of cilta-cel demonstrated 97% overall
response rate and 67% of patients achieved sCR, and 12-month PFS was 77%[16]. At this
time, anti-BCMA CAR-T is only approved for patients with multiple-refractory MM. Due to
the rate of relapse in CAR-T therapy, especially in ide-cel, novel strategies are necessary to
2

stratify patients by risk before CAR-T therapy and assess response kinetics
contemporaneously with the infusion in order to predict the likelihood of relapse.

6.2

Minimal residual disease: a cellular approach
Disease response kinetics in the context of CAR-T therapy are difficult to assess due

to the rapidity with which the therapy can effect a stringent complete response (sCR), defined
by the International Myeloma Working Group (IMWG) as absence of tumor cells in a
primary tumor sample as detected by immunofluorescence and a normal sFLC ratio. sCR is
often achieved within one month of CAR-T infusion, indicating that the tumor is killed
rapidly within the early days surrounding infusion. However, the actual tumor burden is
difficult to define during this window for a number of reasons. First and foremost, bloodbased assays for assessing disease burden in MM have traditionally lacked the sensitivity to
detect low-level disease burden at levels comparable to or exceeding the equivalent disease
burden of a sCR. The ability of a patient to relapse after achieving sCR indicates that some
minimal residual disease (MRD) is still present beyond the level of detection achievable via
immunofluorescence and sFLC assays.
MRD is a much stronger predictor of progression free and overall survival than sCR
alone [13, 17, 18], whether detected by next-generation multicolor flow cytometry
(MFC)[17, 19-22] or molecular methods [18, 23, 24]. Recent meta-analyses of MM studies
have shown that compared to MRD+ patients, MRD- patients have dramatically lower hazard
ratios regardless of disease stage, MRD measurement method and sensitivity, cytogenetic
risk factors, disease setting (newly diagnosed vs relapse, transplant eligible vs not), and depth
of clinical response, including achievement of CR or sCR [25].

3

6.2.1 Multicolor flow cytometry and its use in assessing minimal residual disease
Due to several commonalities between MM and other plasma cell dyscrasias such as
diffuse large B-cell lymphoma and chronic lymphocytic leukemia, it is often useful to apply
techniques developed for other cancers such as V(D)J sequencing[23] and multicolor flow
cytometry (MFC)-based MRD detection[26, 27] to MM. MFC is the diagnostic gold standard
for assessing immunophenotypic MRD due to its high sensitivity and applicability. Next
generation multicolor/multiparameter flow cytometry has sensitivity on the order of 1x10-6;
older MFC technologies retain sensitivity on the order of 1x10-4-1x10-5 [17]. Even this lower
level of sensitivity can be used to inform treatment decisions [17], and a failure to detect
MRD at this level of sensitivity is a strong prognosticator of OS and PFS[18, 22].
Flow cytometry has been in use for MRD assessment in clinics for over two
decades[26] and improvements in technique have caused sensitivity to increase from 10-4,
using the original CD45/CD38/CD138 panel (or an alternative to CD138, up to three colors
total), to 10-6 in some modern versions of the assay utilizing up to 10 colors. Use of MFC in
the GEM2000 trial showed definitively the survival benefit of MRD negativity by MFC[28].
In agreement with early literature, Paiva et al showed that MRD negativity is a better
predictor of PFS and OS than immunofixation or CR with sensitivity of 10-4, and posited that
greater sensitivity might allow MFC to rival PCR-based methods. Sensitivity advances in
MFC have allowed for comparison of benefits for various sensitivity levels: Rawstron et al
showed that there is a comparative benefit per log reduction of sensitivity, correlating to an
extra year, on average, of OS per log reduction[17]. MRD detection is considered a
secondary clinical endpoint for trials, such as the PETHEMA/GEM2012/MENOS65 trial
which has incorporated NGF as the primary MFC protocol[22].

4

Various facilities have their own protocols and panels for MFC detection of MRD,
which may use multiple tubes and 8-10 colors for immunophenotyping. Standard of care
methods include the EuroFlow-based eight color, two-tube panel[29] and some ten-color
panels[30], offering sensitivity down to 2x10-6 to 6x10-6, respectively. In general, at least
seven colors are required to give optimal sensitivity and provide comparable results, allowing
for standardization between facilities[31], but standardization is still a challenge and efforts
to remedy this are ongoing[32]. Another major challenge to MFC-based MRD detection is
the nature of the sample required. A BMB aspirate consists of living cells, so the processing
time between aspiration time and analysis must be as short as possible to obtain the most
comprehensive results.

6.2.2 Tumor infiltration and extramedullary disease
Plasma cells reside in their niche in the bone marrow but can, and frequently do,
migrate throughout the bone marrow and through the entire lymphatic system. Myeloma cells
can form tumors distant from the original tumor site, creating a patchy pattern in the bone
marrow, and causing extramedullary disease in the skull, sternum, lumbar spine, and
elsewhere. Plasmacytomas are identified using MRI or x-ray magnetic bone imaging (MBI),
which have been standard practice in MM diagnosis and treatment for decades[33]. The
disappearance of plasmacytomas identified at diagnosis via MRI or MBI is included in the
IMWG definition of complete response and strict complete response[20]. Importantly,
however, extramedullary plasmacytomas can serve as reservoirs for relapse.
In the last decade, 18fluorodeoxyglucose positron emission tomography/computed
tomography (FDG-PET/CT) has been demonstrated to be an impactful tool for predicting
survival in newly-diagnosed patients by assessing disease burden, and showed some promise
5

in predicting outcomes based on response to ASCT[34-36] and anthracycline-based
chemotherapy[37].The identification of extramedullary lesions with high standardized uptake
values on FDG-PET/CT correlates with worse OS, but does not correlate with M protein
levels [38]. FDG-PET/CT evaluation can be used to target certain regions for BMB beyond
the standard iliac crest site and is used to determine whether ASCT has been effective, and
patients who are FDG-PET/CT negative after ASCT are known to have longer PFS and OS
than those patients who are FDG-PET/CT positive, regardless of CR status[39]. However,
FDG-PET/CT is not effective in identifying diffuse bone marrow involvement[40], and only
has moderate sensitivity and specificity for detecting lesions after treatment[41]. This would
indicate that FDG-PET/CT lacks the necessary sensitivity to detect clonal cells which
constitute a reservoir for relapse.

6.2.3 Circulating tumor cells: an alternative compartment
Circulating tumor cells (CTC) are plasma cells which are shed into the bloodstream
and may be indicative of the primary tumor or an extramedullary tumor, and may be
identified through MFC, PCR, or sequencing of peripheral blood mononuclear cells[42]. No
matter which method is used, the obvious benefit to using this source is its ready availability
and utility. Identification, isolation, and investigation of CTC can also be done by
paramagnetic bead enrichment or microfluidic methods[43], and the genetic material from
these cells is useful for downstream karyotypic, genetic, or genomic analysis such as PCRbased MRD detection[43-45]. CTC are not perfectly identical to primary tumor plasma cells:
CTC adopt a quiescent phenotype and often display genetic features consistent with
subclonality[45, 46]. That said, there is generally good overlap between CTC and primary
tumor plasma cells[47].
6

As a part of the PETHEMA trials, Sanoja-Flores et al showed that the failure to detect
CTC via NGF may lead to false negatives when compared to contemporaneous BM samples,
but may also detect extramedullary disease, and that CTC identification is an independent
predictor of PFS with a higher hazard ratio than BM MRD positivity, suggesting that the
detection of CTC indicates increased tumor burden and/or extramedullary disease[48], and
corroborating their earlier report that CTC levels indicate increased risk for MGUS and
SMM patients[49]. This is in agreement with another report that >100 CTC in a sample on
150,000 PBMCs is an independent risk predictor[50], and a separate report that detection of
CTC immediately before ASCT is an independent negative predictor of OS and PFS[51].
Taken together, the literature suggests that the presence of these cells, though somewhat rare
outside of active disease, can serve indirect measurements of tumor burden.

6.3

Molecular alternatives to NGF/MFC MRD detection
The legacy alternative to MFC/NGF for MRD detection is allele-specific

oligonucleotide quantitative PCR (ASO-qPCR), which has been validated to have
comparable clinical significance at comparable levels of MRD detection to MFC-based
MRD[52]. The principle of all approved ASO-qPCR and all approved NGS assays is the
detection of clonotypic sequences in the rearranged V(D)J region of the clonal plasma cell
genome; however, this is also a major flaw, as a minority of patients have no trackable gene
rearrangement. NGS applicability is approximately 90%[53], while ASO-qPCR applicability
is <80% and requires a complex workflow, including patient-specific primer design and
manufacturing, germline Sanger sequencing, and the creation of a standard curve[54-56].
Digital droplet PCR (ddPCR), an evolution of qPCR, offers higher sensitivity and decreased
workloads at the lab bench by eliminating the need for a standard curve, but still requires all
7

the other steps mentioned for ASO-qPCR. The technique has been shown to have comparable
sensitivity and specificity to ASO-qPCR[57], and has been validated by direct comparison to
NGS and ASO-qPCR in patients following ASCT[58].
Separately, liquid chromatography tandem mass spectrometry (LC-MS) platforms
have been tested for use in MRD detection with a focus on clonal M-protein detection in
serum, based on M-protein isoforms predicted by genomic data[59]. This is an evolution of
the traditional serum protein electrophoresis and immunofixation electrophoresis, which has
been used to quantify serum and urine M-protein for decades. Others have proposed the use
of MALDI-TOF MS to analyze M-protein levels and clonotypes[60, 61], and have
demonstrated the utility of this approach despite potential interference from monoclonal
antibody therapy; and Eveillard et al [62] showed that there was some agreement between the
MALDI-TOF method and MFC. The MS-based approaches tend to separate into two groups:
those using a mass-based approach, [63]; and those seeking specific clonotype sequences
after trypsin digestion[61, 64]. The IMWG has endorsed MS as an alternative to
immunofixation[65] and called for its inclusion in further clinical trials. One promising
report has demonstrated the use of DNA aptamers and a photometric assay in detecting
clonal IgG in serum at levels below the limit of IFE detection in a patient showing a
complete response and MRD negativity (at 10-5 by MFC) who later relapsed [66]. Others
have shown that MS can detect minimal residual disease (in the form of clonal M protein) in
sCR[67]. Finally, a group has shown that MRD+ status by LC-MS (using the clonotypic
approach) correlates with inferior survival, even when MRD negativity by sequencing is
achieved[68]. While these reports are promising, comparison to other MRD detection
techniques is needed, as MRD levels are generally concordant between MFC and NGS-based
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techniques. Derman et al[68] showed a good degree of agreement between methodologies,
but MS has yet to be validated as extensively as other techniques have[58, 69, 70], and the
degree of comparability between LC-MS and established methods has not been determined.

6.3.1 Sequencing approaches in MM: MRD, tumor heterogeneity, and clonal evolution
In the last 15 years, the advent and decreasing cost of next-generation sequencing has
allowed for the study of the genetic basis of several cancer types and complete, personalized,
whole-genome sequencing. NGS of PCR-amplified, tumor-specific markers showed the
potential for identifying MRD using NGS as a main instrument of detection in liquid tumors
based on the ability to identify low frequency aberrant reads[71]. Because unique
immunoglobulin gene rearrangements are characteristic of mature plasma cells, significant
attention has been paid to next-generation sequencing of these genes and their use as
biomarkers [72]. In addition, the evaluation of bulk DNA samples by NGS allows for the
identification of multiple clones and subclones through the identification and frequency
determination of multiple variants of a single gene[73, 74].
At present, the most widespread clinical application of NGS for MRD detection in
MM targets immunoglobulin V(D)J sequences which are characteristic for clonal cells[21,
23]. These systems have been commercialized as the clonoSEQ platform (Adaptive
Biotechnologies, Seattle, WA, USA), formerly known as LymphoSIGHT™ [75, 76] and
LymphoTRACK™ (Invivoscribe Inc., San Diego, CA, USA) systems. clonoSEQ assay is
more common and is routinely used for MRD assessment. Briefly, the procedure calls for
DNA extraction from bone marrow aspirate and PCR amplification of all IGH loci, including
the IGH complete and incomplete loci. The assay is based on universal PCR primers for the
targeted sites, with 39 total PCR cycles and requires a minimum of 500ng gDNA input per
9

sample. The amplified product is then made into a library and sequenced at a median
coverage of 10x per input B cell. The assay requires an initial identification of the tumor
clonotype on diagnosis (defined as a clonotype identified as >5% of reads), and the clonotype
can then be tracked over the course of treatment[77]. LymphoTRACK, in contrast, uses
different targets within IGH. It is designed to be done in-house by clinical labs and can be
run on an Illumina MiSeq[69], whereas clonoSEQ is performed centrally.
A major benefit that NGS offers over other approaches is the ability to supply
qualitative data on mutation landscape, which in other cancers can indicate appropriate
courses of therapy[78, 79]. NGS does have multiple applications with respect to investigating
clonal evolution and druggable mutations, but in the context of MM MRD, the primary value
of NGS is its ability to identify very low frequency variants in a sample.

6.3.2 Circulating tumor DNA and its use in MM observation
An alternative to BMB-derived material is freely circulating cell-free DNA (cfDNA).
cfDNA is the result of normal cellular turnover as chromatin is digested by endonucleases
during apoptosis[80]. Circulating tumor DNA (ctDNA) displays good concordance with
primary tumors via whole exome sequencing (WES) in MM[45] and similar “liquid biopsies”
have been tested in active MM and other types of cancer[81-86], including a liquid biopsy for
EGFR in NSCLC which was recently FDA-approved[87].
In MM, ctDNA-based liquid biopsy has not been extensively validated in clinical
trials. Rather, a handful of trials have yielded conflicting data about the usefulness of liquid
biopsy for cfDNA. Notably, three studies analyzed V(D)J sequences in cfDNA only: Oberle
et al elected to amplify V(D)J sequences via PCR before library preparation and sequencing,
and determined only that MM-indicating V(D)J sequences are cleared from circulation more
10

quickly than M protein[88]; this may indicate a relationship to tumor burden, but this is
disputed by conflicting results from Manier et al[45]. Biancon et al[89] took a similar
approach, amplifying the IGHJ gene in cfDNA. They observed several clonotypes of IGHJ
occurred in either cfDNA or isolated plasma cells, but only 11% of the clonotypes they
identified occurred in both. However, they observed that all tumor-associated clonotypes
were identified in both plasma cells and cfDNA. Finally, Mazzotti et al[90] used the
clonoSEQ platform to analyze both BM samples and cfDNA. Mazzotti’s group saw no
correlation between MRD levels in BM and cfDNA, and saw 18 false negatives (MRD- by
cfDNA analysis, MRD+ by BM analysis) out of 37 samples. However, it is unclear whether
clonoSEQ is appropriate for cfDNA in MM, though it has been demonstrated in DLBCL[23].
Rustad et al[91] presented the first reports using ddPCR in cfDNA in MM to date
(though Drandi et al’s original method used paired BMB and peripheral blood samples[57]),
finding that this method was able to identify mutations in the MAP kinase pathway
consistently, and was able to track tumor burden. However, the choice of the MAP kinase
pathway as a target limits the applicability of this approach to <50%. Li et al were able to
replicate these results, though MRD was never explicitly addressed [92].
Later, Vij et al used a hybrid approach, co-opting the clonoSEQ technique and using
it on both cfDNA and FACS-sorted PBMCs, and comparing this approach to traditional
BMB. They found good concordance between the two methods, as well as correlation
between PBMC/serum clones and BMB-derived clones. Unique among these studies is that
Vij et al also isolated RNA from PBMC and serum to search not only for the clone, but also
to assess the number of clonal cells present[44].

11

A newer development in MM liquid biopsy is the use of low-pass whole genome
sequencing (lpWGS), whereby tumor burden is calculated based on the relative magnitude of
copy number aberrations in the sequenced sample. Pre-treatment application of DLBCL
patients has been shown to predict risk of relapse after CAR-T therapy [93], and in MM,
lpWGS helps define risk categories in multiple-refractory MM patients not receiving CART[94].

6.3.3 Hybrid capture promises high sensitivity and applicability
In the context of both low disease burden, it may prove difficult to detect ctDNA and
differentiate it from germline cfDNA. In addition, sheared gDNA may not be amplified
appropriately if the locus of interest is not flanked by primer sites on both sides of the
fragment. Both of these issues can be ameliorated through the use of hybrid capture[83, 85,
95]. Much like whole exome sequencing (WES) enrichment, hybrid capture uses
oligonucleotide probes to capture specific fragments for high-throughput NGS.
Several studies have used hybrid capture to identify mutations and track disease
progression in several other cancers, including breast cancer[83], lung cancer[78, 83, 96],
and diffuse large B-cell lymphoma (DLBCL) [81, 86, 97] which has many parallels with
MM. First published in 2014, CaPP-Seq (Cancer Personalized Profiling via Sequencing) was
proposed as a method to identify somatic mutations and copy number aberrations in nonsmall cell lung cancer (NSCLC) patients. Newman et al applied an iterative algorithm to a
large cohort of NSCLC tumor genomes and exomes, aiming to identify “selectors” which
would find the greatest number of somatic mutations and fusion breakpoints at the shortest
probe length. The group then optimized the probes on an independent NSCLC tumor cohort,
and in testing patient samples, observed maximal sensitivity of 85% and maximal specificity
12

of 96%, with improvements as the disease progressed from stage I onwards. In addition,
owing to the difficulty of biopsy in NSCLC and the confounding effects of radiotherapy on
PET-CT, the authors used CaPP-Seq as a surrogate for tumor burden[96]. Working from the
same lab as Newman, Scherer et al demonstrated high sensitivity in DLBCL and identified
sequences predictive of relapse [23]. The technology is marketed under license using the
Roche Avenio branding. Using a CaPP-Seq schema generalized for multiple cancers, Clark et
al would use a similar hybrid capture design, along with unique molecular identifiers (UMI)
in cfDNA and associated solid tumors, identifying disease evidence at sensitivities over 80%
at a mutant allele frequency <0.25% with 100% positive predictive value, and compared
favorably to established PCR methods[83].
In MM, hybrid capture-based schemes have been used to investigate cfDNA during
active disease, but not to investigate MRD specifically[85, 98, 99]. Three investigations
separately attempted to identify known oncogenes and IGH loci via hybrid capture, then use
deep sequencing to identify mutants, translocations, and copy number aberrations. The
studies all vary in DNA source, sample input, and targets, and among these, the target size
and input are likely the most important. Common regions include member genes of the MAP
kinase pathway and IGH. Theoretically, larger panels which target many loci would have
greater sensitivity than smaller ones. However, there is an upper limit, as Manier et al’s WES
approach only identified 20-30 genes which were useful in analysis. The sensitivity of the
hybrid capture approach has not been evaluated in minimal residual disease in MM, as all of
the above assays were evaluated in active disease. Though each shows high sensitivity, the
ability to detect minimal residual disease using hybrid capture may depend on more than just
identifying canonical mutations.
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6.4

Challenges and future directions

6.4.1 Technical and comparative challenges
The ability to define and detect residual disease at sensitivity levels >10-5 have given
the myeloma community a much better understanding of the depth of response achieved by
existing and novel therapies, the increasing depth of response driven by modern therapies has
led to their becoming frontline strategies. Technical challenges for each approach are welldocumented, but some universal challenges remain.
MFC is the gold standard in cancer treatment due to its near-universal applicability
and sensitivity, but it is not without its drawbacks. All bone marrow-based assays require
poorly tolerated and inefficient bone marrow biopsies (BMB)[100]. BMB are uncomfortable
and invasive for patients and have a failure rate of up to 25% due to hemodilution[100].
Tumor heterogeneity is frequent in MM and a single BMB could miss some of the
heterogeneity of the tumor[6]; this can be remedied somewhat via sequencing approaches or
targeted biopsies (based on imaging) [45, 101], but the patchy nature of MM tumor
infiltration in the medulla, as well as the presence of extramedullary disease, means that blind
BM aspiration alone is an imperfect sampling strategy[102]. Finally, rapidly proliferating
tumors may not be detected in the semiannual or annual intervals used for BMB and MFC
analysis until they become clinically apparent, by which point the value of MRD detection is
moot.
A common theme in MRD research, especially in myeloma, is that a negative result
in one MRD testing modality does not necessarily predict whether a patient is truly “cured,”
or even whether they will test positive for MRD by another modality. The various MRD
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assessment techniques have varying sensitivities, interrogate different compartments, and an
MRD- result often only indicates that the time before relapse is prolonged.
A variety of groups have attempted to measure MRD in different ways, and MRD
measurement is not standardized in methods or reporting. While ddPCR, NGS, and MFC
have all been shown to be roughly comparable[58], efforts to standardize MRD reporting
have only come to fruition in the last few years[102], so older studies must be compared in
light of their differences in design and methodology.
Sensitivity of both MFC and NGS have increased to the point that sensitivity is
ultimately bound by sample input: for example, an input of 106 cells into NGF analysis can
reasonably be expected to have a sensitivity of 10-6, and the same is roughly true (though not
entirely) for NGS-based approaches[103]. Though the sensitivity of NGS approaches is
comparable to, or surpassing, that of NGF, increased sensitivity comes with its own technical
challenges, not least of which the necessary input material to achieve greater sensitivity: due
to the statistical “rule of three,” to achieve a 10-7 sensitivity using NGF, 3x107 bone marrow
cells would be necessary[104, 105]. For a complex NGS assay involving hybrid capture and
NGS, library preparation and multiplexing each require subsampling steps. Assuming
sufficient read depth, the probability of detecting target molecules in a healthy background is
determined by Poisson probability distributions, and this probability decreases based on the
number of subsampling steps[106]. NGS approaches are also limited by PCR-induced bias
and the error rate of the sequencing platform used. Finally, a common practice in NGS-based
approaches is sample multiplexing, which can produce cross-contamination and index
hopping, leading to false positives[107]. While multiplexing, subsampling, and unnecessary
PCR cycles could be avoided or mitigated, this has the potential to make each assay
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extravagantly expensive. Some researchers have suggested that NGS assays be performed in
triplicate, further adding to the cost of these techniques[56]. Pushing to 10-7 or deeper may
not be possible with current technology or even particularly informative unless that level of
response can be shown to have a survival advantage over detection at 10-6, the current limit.
While increasing sensitivity of MRD assays may be worthwhile, a more important challenge
may simply be to have a greater proportion of patients achieve sustained MRD negativity
after therapy. In this light, MRD outcome may be highly useful as a secondary endpoint for
clinical trials in MM.

6.4.2 Minimizing sequencing error
Error is inevitable when using NGS, and although modern sequencers have improved
error rates compared to previous generations, error rates on the order of 1x10-4 bases read are
standard when sequencing at great depth [108]. Furthermore, PCR misincorporation errors
can occur at rates ranging from 1.5x10-4 (Taq) to 5.3x10-7 (high-fidelity Q5
polymerase)[109]. To mitigate sources of sequencing and polymerase errors, multiple error
suppression methods have been proposed.
Molecular barcoding, first proposed by Miner et al [110], is the process of
introducing a degenerate nucleotide tag sequence to each input DNA molecule during library
construction, which allows sequenced molecules to be identified as authentic sequences,
duplicates (thus allowing quantitation of duplicates), and further allows the identification of
errors within individual molecules [111, 112]. Use of these nucleotide barcodes, or unique
molecular identifiers (UMIs) allowed improvement of error detection by requiring the
identification of “super-mutants,” mutants present on ≥95% of reads of a single molecule
family. This approach improved the accuracy of NGS-based analysis of very low-frequency
16

mutation rates in human germline DNA and other sources, showing substantial decreases in
variant allele frequencies identified by these modalities[112].
Duplex sequencing, an extension of these ideas, incorporates dual UMIs, one unique
tag on each end of the insert molecule, and requires in silico matching of the sequenced
strands into read families to confirm the authenticity of variants present on both strands, as
opposed to polymerase errors introduced at any point, even the initial amplification step.
Drawing on earlier approaches, this method generates a single strand consensus sequence
(SSCS) from each strand of the original molecule, and then reconciles the SSCS from both
strand families into a dual strand consensus sequence (DSCS) for the insert molecule. As
such, variants only recognized on the read family for one strand can be classified as
polymerase errors, as are any variants identified in any smaller portion of the reads for one
strand[113]. One drawback of Duplex sequencing, however, is that reconciling SSCS to
DSCS is difficult, and the majority of reads are not able to be reconciled into DSCS. As a
result, it is impractical and uneconomical to sequence samples to a duplex depth (depth of a
locus covered by DSCS-reconciled reads) to an equivalent SSCS depth[114].
Additional efforts to improve sequencing accuracy include in silico error suppression
methods, predicated on the fact that sequencing errors are stereotypic, and the predominant
class of errors (G→T transversions, C→T and G→A transitions) are the result of oxidative
damage during enzymatic and hybridization reactions. Furthermore, the possibility of a given
base being a false mutation can be judged against the probability of finding a similar
mutation in the same locus in a panel of healthy controls, allowing greater confidence in true
variant calls when a panel of normal samples is included in the analysis[115]. Another novel
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strategy to detect variants accurately at low frequencies is to specifically look for phased
mutants, i.e. two specific variants in short succession on a molecule[116]

6.5

Utilizing highly sensitive methods of assessing disease burden for prognostication
of disease course
While the correlation between various genetic factors and disease outcome has been

understood for decades, and while sequencing studies in the past fifteen years have
elucidated the effects of specific mutations, using these data in real-time to observe and
potentially predict therapy response is a fledgling field. The relative invasiveness of the main
MRD detection methods suggest that assays relying on the bone marrow compartment are
not ideal for providing useful data in dynamic treatment settings. However, many schema
relying on peripheral blood have demonstrated prognostic ability, both in MM and in other B
cell malignancies.
This discussion is particularly relevant in the context of chimeric antigen receptor T
cell therapy (CAR-T), which has a unique response profile. As described above, CAR-T
therapy causes durable responses in roughly half of patients, while the other half experience
disease progression within months of infusion. Combined with the significant turnaround
time of six weeks to manufacture autologous CAR-T cells and the significant expenses
involved in the therapy, the ability to predict which patients would respond well to CAR-T
therapy could guide treatment decisions, thereby preventing a waste of time and resources.
On the other hand, the novel nature of CAR-T treatment, combined with extensive inpatient
time surrounding treatment, makes CAR-T therapy an excellent subject for comprehensive
and rigorous study.
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Analysis of sFLC and immunofixation of immunoglobulins surrounding CAR-T
therapy indicates that the change from baseline M protein level presents as a rapid decline
over the first month before plateauing and eventually rising if the patient relapses, consistent
with responses of this biomarker to traditional therapy [117]. In addition, outside the CAR-T
context, Manier et al [45] show that disease burden assessed by cfDNA low-pass WGS
correlates with M protein levels and disease burden. Data demonstrating the utility of the LCMS approach described earlier in the context of CAR-T therapy are not available, but could
provide a promising avenue to utilize liquid biopsies in dynamic treatment settings.
In the context of diffuse large B cell lymphoma, our group has shown the ability of
CaPP-Seq to discriminate patients into “responders” and “nonresponders” on the basis of a
five-fold decrease in variant allele frequency in ctDNA within seven days post-infusion of
anti-CD19 Axicabtagene ciloleucel (Axi-cel)[118]. To our knowledge, this study is unique in
that it investigates disease burden in a very short duration after transfusion, whereas the
majority of studies of CAR-T therapy for lymphoid malignancies do not examine disease
responses for at least one month after infusion, when response and MRD status are evaluated.
However, given that ide-cel CAR-T cells expand to their maximum number during the first
week of therapy before slowly declining over several months[15], it is possible that tumor
burden may regress within the first week of therapy[Martinez], consistent with Deng et al’s
study of DLBCL.
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7

Justification, hypotheses, and aims
Chimeric antigen receptor T cell therapy is a novel adoptive cell therapy which shows

considerable promise in multiple myeloma and leads to rapid shrinking of the tumor within
one month of infusion[14]. CAR-T numbers peak within one week of infusion[15], but the
most sensitive methods of detecting residual tumor cells (Minimal Residual Disease, MRD),
methods which are prognostic in nature[13, 17, 18]. are not able to monitor disease burden in
such a dynamic timeframe owing to their reliance on poorly-tolerated bone marrow biopsies.
An attractive alternative to bone marrow biopsies presents itself in cell-free DNA (cfDNA)
which is shed into the bloodstream by apoptotic cells throughout the body. Circulating tumor
DNA (ctDNA) displays good concordance with whole exome sequencing (WES) in MM[45]
and similar “liquid biopsies” have been tested in active MM and other types of cancer[8187]. A unique challenge of detecting low disease burden in cfDNA is the expected low copy
number of ctDNA, but this may be ameliorated through the use of hybrid capture[83, 85, 95],
which uses oligonucleotide probes to capture specific fragments for enrichment before highthroughput NGS. We have designed a custom hybrid capture probe panel and intend to apply
it to serial cfDNA samples of patients receiving CAR-T therapy in order to test results
demonstrated by Deng et al[118], who showed that a fivefold decrease in variant allele
frequency, as determined by ctDNA capture sequencing, within seven days of CAR-T
infusion was predictive of treatment response in diffuse large B cell lymphoma (DLBCL).
The central hypothesis is that our approach, using cfDNA, hybrid capture, and deep
sequencing, which we refer to as M5Seq (myeloma molecular residual disease monitoring by
massively parallel mutation sequencing), will have sensitivity equivalent to or exceeding
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standard of care MRD measurement techniques. Furthermore, we hypothesize that the
sequencing data which results will be useful for predicting outcomes.
The specific aims of this project are:

7.1

Aim 1: Determine the limit of detection and limit of linearity of the M5Seq assay
Next generation sequencing, using advanced digital error suppression and molecular

barcodes, is able to identify and quantitate ultra-low frequency variants in genomic and cellfree DNA, including the identification of ultra-low frequency tumor-derived variants when
using custom hybrid capture panels[96], at allele frequencies of 0.01% and lower. Similarly,
standard of care MRD assays frequently achieve this level of sensitivity [29, 75]. I
hypothesize that M5Seq will be able to detect variants with similar sensitivity to existing
methods, and that it will retain linearity down to its limit of analytical sensitivity. In order to
demonstrate the limit of sensitivity of M5Seq, spike-in libraries consisting of serial dilutions
of tumor-derived DNA in healthy DNA will be captured and sequenced, and the variant
allele frequency for individual variants will be plotted down the dilution series to a lower
limit of 10-6. To eliminate the influence of confounding variants, a panel of healthy cfDNA
controls will be captured and sequenced, and variants identified in more than 1 normal
sample will be filtered. In addition, population-level variants identified in the ExAC browser
above a population allele fraction of 1% will be filtered.

7.2

Aim 2: Investigate the informative and prognostic abilities of M5Seq in patients
receiving standard of care treatment.
Exome sequencing demonstrates strong concordance between cfDNA and tumor

gDNA in lymphoid malignancies[23, 86, 96] including MM[45]. Furthermore, ctDNA
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sequencing is predictive of outcomes in DLBCL, including in the days following CAR-T
therapy[23, 97, 118]. I hypothesize that when utilizing M5Seq, variants called in bone
marrow and contemporaneous samples will demonstrate good concordance. I further
hypothesize that change in VAF within two to seven days after CAR-T infusion will be
predictive of outcomes. First, we intend to sequence matched, contemporaneous pretreatment cfDNA and bone marrow samples taken from treatment-naïve MM patients to
demonstrate inter-compartment concordance and applicability of ctDNA sequencing as an
indirect indicator of tumor burden. Second, we intend to evaluate changes in VAF over the
seven days after CAR-T infusion and determine whether these changes are correlative with
IMWG-defined response at D+30 or survival.
The successful accomplishment of Aim 1 will allow for accurate quantitation of lowfrequency, tumor-derived variants and establish the analytical sensitivity of the assay when
compared to MRD assays. The successful accomplishment of Aim 2 will demonstrate the
clinical and prognostic abilities of M5Seq, providing better information to clinicians and
scientists as CAR-T therapy in MM evolves.
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8

Methodology
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Figure 1: Schematic of methodology employed
The sample processing workflow for all samples consisted of six discrete steps (fig.1,
from top left following arrows). DNA was extracted from patient plasma and primary tumor
samples, and the extracted DNA was assessed for quality in order to determine which
timepoints to assess, when possible. Sequencing libraries were constructed from these DNA
samples, and the libraries were enriched using hybrid capture. Captured libraries were
sequenced and the resulting data were analyzed using a publicly available bioinformatics
process.

8.1

Sample acquisition and sources
Clinical samples were acquired from two different sources: first, a standard-of-care

clinical specimen collection protocol (PA19-0436) for newly-diagnosed MM patients
(“NDMM cohort”) receiving bortezomib, lenalidomide, and dexamethasone therapy (VRd)
and an autologous stem cell transplant. Of these, 11 patients were identified as being
candidates for analysis due to the presence of multiple induction samples and post-transplant
samples, and of these, one bone marrow-derived library failed QC. Second,
relapsed/refractory MM (RRMM) patients receiving ABECMA (idecabtagene vicleucel,
Bristol Myers Squibb, referred to herein as “ABECMA protocol” or “ABECMA cohort”)
anti-B Cell Maturation Antigen CAR-T therapy (n=19).

8.2

Spike-in experiments
Genomic DNA (gDNA) from peripheral mononuclear blood cells (PBMC, from MD

Anderson Cancer Center blood bank) and cell lines U266 and H929 (American Type Culture
Collection) was extracted using the Qiagen Blood Spin mini Kit according to manufacturer’s

24

protocol and quantified using Qubit 3.0 fluorometry (ThermoFisher Scientific). DNA was
sonicated to 150bp using a Covaris M platform, and the sonicated product was diluted to
50ng/μL. The following samples were prepared for library prep, using 1/10 serial dilutions
(see table 1 for DNA input and expected allele fractions). Positive controls contained only
cell line (U266 or H929) DNA, processed as described; negative controls contained only
PBMC DNA, again processed as described. Each library had an input of 1500ng of DNA, as
quantified before shearing per manufacturer directions, and suspended in 30µL of ultrapure
water.

Table 1: Experimental design of spike-ins
Variant Allele Freq.
1 (Positive Control)
0.1
0.01
0.001
0.0001
0.00001
0.000001
0 (Negative Control)

8.3

log10

Cell Line DNA (ng)

PBMC DNA (ng)

0
-1
-2
-3
-4
-5
-6
NA

1500
150
15
1.5
0.15
0.0015
0.00015
0

0
1350
1485
1498.5
1499.85
1499.985
1499.9985
1500

Nucleic acid extraction
In accordance with the MD Anderson Cancer Center clinical specimen protocol

PA19-0436, 10mL blood samples were collected from patients at diagnosis of MM and twice
centrifuged to obtain plasma.
10mL blood samples were collected from patients receiving ide-cel on the following
schedule. Samples were twice centrifuged to obtain plasma.
•

At apheresis for CAR-T manufacture
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•

Days -5, 0, +1, +4, +7, +14, +21 +28 from CAR-T infusion (±2 days for each timepoint
before 14 days, then ±3 days for subsequent timepoints)

•

Every 30 days after infusion until discontinuation or withdrawal, up to 120 days
In addition, 16 banked plasma samples from the MD Anderson Cancer Center blood

bank were thawed and aliquoted into 15mL tubes. All researchers were blind to the identity
or clinical characteristics of the normal samples, which contributed to the Panel of Normals
(PoN).
cfDNA was extracted from plasma using the QIAGEN Circulating Nucleic Acid kit
(QIAGEN, Hilden, DE) according to manufacturer’s protocol and eluted in 35μL PCR-grade
water. Eluent was then quantitated using the Qubit 3.0 and Qubit High Sensitivity reagents,
and analyzed using Agilent Tapestation D1000 to assess quality and purity of cfDNA.
Bone marrow samples were processed by the MD Anderson Cancer Center
Lymphoma Tissue Bank and viably cryopreserved. These samples, containing over one
million cells each, were spun down and washed twice in phosphate-buffered saline before
resuspension in Qiagen RLT Plus buffer. Bulk nucleic acids were extracted using the Qiagen
Allprep kit. DNA was quantitated using the Qubit 3.0 with Qubit High Sensitivity reagents
before shearing using the Covaris M platform.

8.4

Library construction, hybrid capture, and sequencing
The samples then underwent library construction using Twinstrand library and

capture kits (Twinstrand Biosciences, Seattle, WA), using dual index universal molecular
identifier stubby indexing adapters (UDI). All library preparation was carried out in 96 well
plates to limit variability. End repair and A-tailing was performed in a thermocycler (20℃
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for 30min, then 65℃ for 30 minutes), followed by UDI adapter ligation for one hour at 20℃
in a thermocycler. The ligated product was bound to a 0.8x suspension of SPRI beads and
cleaned using 70% ethanol to remove adapter dimers and enzymes from the ligation reaction
before resuspension in low-TE buffer. The product was conditioned using Twinstrand
Library Conditioning Mix by incubation at 37℃ for one hour. The product was then
amplified using PCR (10 cycles) and cleaned with a 1.0x ratio of SPRI beads. Final libraries
were analyzed via Agilent Tapestation to check for quality, fragment size, and purity. 1μL of
library was diluted 1/10 and used for QC, then stored for low-passage whole genome
sequencing (lpWGS).
The first of two overnight hybridization reactions was conducted using a custom
probe set at 65℃. The hybridization mixture incubated for no less than 14 hours (and up to
20) with biotinylated probes before being transferred onto washed streptavidin beads and
incubating for another 45 minutes to capture hybridized molecules on the beads. Washes
occurred at room temperature, following manufacturer protocols. Captured libraries were
amplified by PCR (16 cycles) and cleaned with a 1.0x ratio of SPRI beads before quantitation
and QC.
The second overnight hybridization proceeded the same as the first hybridization,
except that the incubation temperature was 62℃, again in keeping with manufacturer
protocol. Captured libraries were amplified using PCR (6 cycles) and cleaned with a 1.0x
ratio of SPRI beads before final quantitation and QC. Captured libraries were stored in lowTE buffer in 96 well plates at -20℃.
Following manufacturer recommendation for achieving maximum mean duplex
depth, samples were sequenced according to the following scheme:
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# Paired End Reads = 1.08x106 x DNA input (ng) x Conversion Factor
Such that 1.08x106 is a panel-specific requirement, and the conversion factor is an
integer n=1 for sheared gDNA and n=3 for cell-free DNA. So, for example, bone marrow
samples with 250ng input would call for:
# PE reads = 1.08x106 x 250ng x 1 = 270 million reads
And a cfDNA sample with 50ng input would require:
# PE reads = 1.08x106 x 50ng x 3 = 162 million reads
Samples were pooled proportional to the number of reads required and sequenced on
S4 lanes on an Illumina NovaSeq system, using paired-end 100bp reads.

8.5

Capture panel design
An initial capture panel design was created using hg19 according to the method

described by Newman[96] based on MM exomes publicly available in the Multiple Myeloma
Research Foundation CoMMpass database (Green lab, unpublished data). This panel,
MM_M4, was then significantly redesigned and modified. First, MM_M4 was lifted over
using the UCSC Genome Browser to hg38. Each existing probe was analyzed for secondary
structure and number of BLAST hits. Probes with ΔG°>-15 for RNA folding, and probes
with >5 BLAST hits, length of >70bp, and >80% similarity were eligible for removal from
the panel. Genes in these categories typically consisted of somatic hypermutation targets and
Ig genes, respectively.
At this point, the decision was made to salvage these regions when possible, as the
mutational signature of MM does include several SHM targets and a clonotypic peptide
sequence. Regions to be probed were identified by selecting the 500 most-commonly
mutated genes and noncoding regions in the MM genome [119]. The exon start and stop
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locations in hg38 were pulled for each region and compiled. These short regions were tiled
and QC’d as described in the previous paragraph. Preference for salvage was given to known
oncogenes such as BRAF, KRAS, NRAS, and MYD88. The final panel, manufactured as
pan00309 (M5Seq) was manufactured by Twinstrand Biosciences and covered 186kb.

8.6

Sequence data analysis and VFC calculation
The bioinformatics analysis used for this process is the CAPP_SEQ_pipeline,

publicly available on GitHub (https://github.com/Green-LabMDACC/CAPP_SEQ_pipeline). FASTQ R1 and R2 read files were checked for quality
using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and then
converted to unaligned BAM files using the fgbio FastqToBam package
(http://fulcrumgenomics.github.io/fgbio/). UMIs were extracted using the fgbio
ExtractUmisFromBam package, and the reads were then converted to interleaved FASTQ
files using the Picard SamToFastq (https://github.com/broadinstitute/picard) and aligned to
the hg38 genome using BWA (http://bio-bwa.sourceforge.net/bwa.shtml) and Picard
MergeBamAlignment packages. Reads were then grouped by UMI using fgbio
GroupReadsByUmi and, depending on whether duplex consensus reads were required or not,
were called using fgbio CallDuplexConsensusReads or CallMolecularConsensusReads (for
single strand consensus), with a minimum of 2 matched reads to be called. The data were
then again converted to interleaved FASTQ as described above. Reads were filtered for
quality and consensus using fgbio FilterConsensusReads and clipped using fgbio ClipBam.
Variants were called using GATK HaplotypeCaller and Mutect2
(https://gatk.broadinstitute.org/hc/en-us). Final reads were enumerated using bcftools, and
data were filtered such that only variants with depth greater than 100 were considered for
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further analysis. In addition, variants previously identified in the Panel of Normals
(previously called using DSCS) are filtered at this stage. At this stage, variant allele
frequency (VAF) is quantitated for every called variant.
The Panel of Normals (PoN, n=15) were processed first and variants were called
irrespective of variant allele frequency (VAF) or known population allele frequency (PAF),
using DSCS. All variants present in more than one member of the cohort (equivalent PAF =
6.67%) were filtered from subsequent samples. In addition, all called variants are annotated
with PAF as listed in the ExAC database[120] by SeattleSeq[121] and any called variants
with PAF >1% are filtered from further analysis. SeattleSeq also annotated SNPs in the
dbSNP database[122] and variants identified as being repeats using the repeatMasker
function; these annotated variants were also filtered from analysis.
Spike-in series were screened as described above. Variants were called using DSCS
in the U266+ and H929+ samples and using SSCS for all subsequent samples. The VAF of
filtered variants identified in the positive control (U266+ and H929+, see Table 1) and not in
U266- were plotted against the expected allele fraction (EAF), the dividend of the observed
VAF (oVAF) in U266+ and the dilution factor.
Calibration timepoint samples (i.e. samples taken contemporaneously before therapy
intervention, either via VRd or pre-CAR-T lymphodepletion) were processed using both the
DSCS pipeline in order to call variants with low probability of being sequencing or
polymerase errors, and using the SSCS pipeline for comparison. Longitudinal samples,
however, are processed on the SSCS pipeline, with special attention paid to the variants
defined by the calibration sample’s DCSC data.
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After filtering, final sequencing data were processed in Excel, including Variant
Allele Frequency Fold Change (VFC), the quotient of the average filtered VAF at a given
timepoint over the D+0 average filtered VAF. Survival analysis was performed, and hazard
ratios were calculated, in Graphpad Prism 9. Graphics were generated using Python’s Plotly
package, Graphpad Prism 9, or Excel. Statistical analyses were performed in Graphpad Prism
9.
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9
9.1

Results
M5Seq panel validation in-silico
The redesigned capture panel was tested in silico to assess the applicability of the

M5Seq panel to the initial 1,212-tumor design and validation cohorts used to design the
MM_M4 panel. Called variants from each tumor which were located in the regions mapped
by the probes were counted as detected variants.
Of the 1,212 tumors, 1,173 tumors contained mutations covered by the M5Seq panel
(96.8% applicability rate). 315/1,212 tumors had 1-5 mutations covered (26.0%), 383/1,212
tumors had 6-10 mutations covered (31.6%), 399/1,212 tumors had 11-25 mutations covered
(32.9%), and 76/1,212 tumors had >25 mutations covered (6.3%)(fig.2b). The greatest
number of mutations identified in one tumor was 317. The mode of the data was 6 mutations
covered per tumor, and the median was 9 mutations covered per tumor (fig.2a).

Figure 2: Distribution of mutations directed by M5Seq in silico A) Distribution of captured
variants in testing and validation cohorts of the M5Seq panel. B) Percentage of tumors in
testing and validation cohorts with a given range of mutations captured by M5Seq.
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9.2

Analytical sensitivity of M5Seq assay

Figure 3: Results of spike-in experiments A) observed vs expected variant allele frequencies
(oVAF vs eVAF) for spike-in experiments using the U266 cell line and counting single
strand-supported variants which were originally confirmed via duplex sequencing in the
calibration sample. B) oVAF vs eVAF for spike-in experiments using the H929 cell line and
counting single strand-supported variants which were originally confirmed via duplex
sequencing in the calibration sample. C) oVAF vs eVAF for spike-in experiments using the
U266 cell line and only using duplex sequencing for all libraries. D) oVAF vs eVAF for
spike-in experiments using the H929 cell line and only using duplex sequencing for all
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libraries. E) Comparison of sequencing depth in U266 spike-in libraries when using single
strand consensus sequencing vs duplex consensus sequencing.
Spike-in experiments were conducted using the U266 and H929 cell lines. Observed
allele fraction (oVAF) were plotted against expected allele fraction (EAF), as calculated
using the method in the Methods section. Briefly, for each variant in the U266+ library which
was not filtered out, the VAF of the variant was calculated by dividing the number of variant
reads by the number of total reads at the locus (oVAF). The oVAF in the U266+ library was
then divided by the dilution factor to compute EAF for each variant. This was plotted against
the oVAF for the corresponding variant.
When using DSCS support, the U266 spike-in series demonstrated a limit of
sensitivity at 2x10-4 and remained linear on a logarithmic scale down the dilution series to an
EAF of 2x10-4 (fig.3c) When using SSCS support, the U266 spike-in series demonstrated a
limit of sensitivity at 3x10-5 and a limit of linearity at an EAF of 10-4 (fig.3a)
When using DSCS support, the H929 spike-in series demonstrated a limit of
sensitivity of 10-4 and remained linear on a logarithmic scale down the dilution series to an
EAF of 10-4 (fig.3d) When using SSCS support, the H929 spike-in series demonstrated a
limit of sensitivity of 3x10-5 and a limit of linearity at an EAF of 10-4 (fig.3b).
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9.3

Newly Diagnosed Multiple Myeloma (NDMM) cohort

9.3.1 NDMM patients, samples, and calibration timepoints
11 newly diagnosed MM patients, having all three of a calibration bone marrow
sample, contemporaneous plasma sample, and longitudinal plasma samples for response
assessment were considered for analysis here. Patients began physician-ordered frontline
therapy after collection of samples. Of the 11 patients, one (MM0008) had their calibration
bone marrow library fail sequencing QC. A total of 10 patients are analyzed here.
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9.3.2 Inter-compartment comparison of variants identified in NDMM samples

Figure 4: Inter-compartment concordance in NDMM cohort A) Number of duplex consensus
variants called in bone marrow, cfDNA, and in both compartments in the NDMM cohort. B)
Number of bone marrow variants clearing stringent filters for germline variants and number
of these variants enumerated in cfDNA.
Comparison of pre-treatment variants called in DSCS between bone marrow and
cfDNA compartments in this cohort indicates a median of 4 variants called in bone marrow
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(range 1-10) and a median of 9 variants called in cfDNA (range 4-39). The median number
of concordant variants was 2 (range 0-9). The median concordance, or percentage of variants
identified in both compartments, was 21% (range 0%-90%). Of the 10 patients, MM0015 had
the greatest mutational burden with 39 total variants identified, whereas MM0018 had the
lowest mutational burden with only 5 total variants identified (fig.4a)
Comparison of SSCS-called variants in cfDNA to DSCS-calibrated BM variants
indicates that a minority of the BM-calibrated variants are recovered in cfDNA. While all
three filtered, calibrated bone marrow variants were recovered in the cfDNA of patient
MM0031, none of the two bone marrow variants were recovered for MM0014. For patient
MM0012, despite having 51 filtered variants calibrated, only six were recovered in cfDNA
(fig.4b).
Variants identified in the calibration timepoints consisted predominantly of somatic
hypermutation targets such as BTG2, BCL6, BCL2, and DTX1, of which multiple variants per
gene were detected in every pre-treatment PA19 sample. Other frequent SHM variants
identified were CXCR4, and PAX5. At least one variant in the IRF4 oncogene was identified
all but one sample (MM0021_001, a bone marrow sample), but other oncogenes were
detected at much lower rates: TRAF3 variants were detected in a majority of patients, while
IRF8 and TP53 variants were only detected in a minority, and a BRAF variant was identified
in a single sample, the cfDNA sample MM0019_002, and not confirmed in the matching
bone marrow sample MM0019_001 (fig.5a). The panel did not detect variants of known MM
oncogenes NRAS, FAM46C, or DIS3.
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Figure 5: Comparison of calibration timepoints of NDMM and ABECMA cohorts A)
Frequency of variants identified for selected genes in the NDMM cohort. B) Frequency of
variants identified for selected genes in the ABECMA cohort. C) Comparison of variants
identified in bone marrow of both cohorts. D) Comparison of the number of stringently
filtered variants enumerated in cfDNA at calibration from both cohorts. E) Average VAF,
measured using duplex consensus sequencing, at the calibration timepoint in both cohorts. F)
Average VAF of enumerated variants in cfDNA at the calibration timepoint.
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9.4

ABECMA

9.4.1 ABECMA patients, samples, and overall outcomes
Also included in analysis were 19 patients receiving idecabtagene vicleucel antiBCMA chimeric antigen receptor T cell therapy. These patients were enrolled in a separate
clinical trial (table 2).

Table 2: Characteristics of ABECMA cohort
Sex, % (n)

37% Female (7)
63% Male (12)
BCMA therapy: 21% (4)
IL-15: 5% (1)
Deceased: 1
PD: 1
SD/MR: 4
PR: 1
VGPR: 2
CR: 1
sCR: 6
No infusion: 3
Positive: 4
Negative: 10
Deceased:1
No infusion: 3
Unknown: 1
PD: 0
SD/MR: 0
PR: 1
VGPR: 1
CR: 0
sCR: 5
Deceased:7
Unknown: 5
Positive: 1
Negative: 2
Deceased: 7
Unknown: 9

Notable previous therapies
Day 30 IMWG Response (Progressive
Disease (PD), Stable Disease/Marginal
Response (SD/MR), Partial Response (PR),
Very Good Partial Response (VGPR),
Complete Response (CR), Stringent
Complete Response (sCR)

Day 30 MRD Status (EuroFlow method)

3 Month Response

3 Month MRD Status
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Of the 19 evaluable patients, 11 died as of 27Apr2022, including two (AB14 and
AB16) who died before receiving their infusions; as such, their pre-treatment samples are
included in analysis of inter-sample concordance, but longitudinal analysis is not possible.
The causes of death, when reported, were myeloma and/or related complications (3),
cytokine release syndrome (1), and COVID-19-related acute respiratory distress syndrome
(1). The median survival after infusion was 195 days. One patient, AB17, received an
infusion but did not provide a calibration BM sample; this patient is not one of the 19
analyzed. Four patients received previous anti-BCMA therapy before receiving CAR-T
infusion. Of the four, two have died. Of the two, one death was attributed to COVID-19
ARDS, while the other cause of death was unreported.
The clinical courses of two patients, AB11 and AB13, are notable. AB11 received
their CAR-T infusion and experienced grade 5 cytokine release syndrome (CRS),
hemophagocytic lymphohistiocytosis (HLH), and a systemic bacterial infection. The final
sample from AB11 was collected on D+7 and was captured and sequenced. AB11 died on
D+14 due to complications; MM was not listed as a cause of death. Due to the unique clinical
outcome, and also owing to the abnormally high cfDNA yields from her plasma samples, the
patient will be analyzed separately when appropriate. Patient AB13 received their infusion
and was diagnosed with stable disease per IMWG criteria at her one-month follow-up. AB13
died of COVID-19-related acute respiratory distress syndrome 42 days after infusion; as
such, this patient will be censored from survival analysis as well; however, the change in
VAF over time is still useful with respect to their D+30 response.

9.4.2 Inter-compartment concordance of variants identified in ABECMA samples
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Figure 6: Inter-compartment concordance in ABECMA cohort A) Number of duplex
consensus variants called in bone marrow, cfDNA, and in both compartments in the NDMM
cohort. B) Number of bone marrow variants clearing stringent filters for germline variants
and number of these variants enumerated in cfDNA at multiple timepoints, including at
calibration (contemporaneous with bone marrow aspiration), D+0, +2, and +7 of CAR-T
infusion.
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Comparison of pre-treatment variants called in DSCS between bone marrow and
cfDNA compartments in this cohort indicates a median of 19.5 variants (range 8-42) called in
bone marrow and 36 variants (range 3-81) called in cfDNA, of which a median 11 variants
(range 2-31) were identified in both compartments. The median concordance, or the
percentage of variants identified in both compartments from the total number of variants, was
29% (range 6%-61%). Of the 18 patients evaluable for inter-compartmental concordance,
AB03 had the lowest mutational burden with 19 total variants, whereas AB16 had the highest
mutational burden with 86 variants identified (fig.6a)
The number of traceable variants over time is relatively stable and provides useful
information about the accuracy of VFC calculations. In all cases, the number of variants
calibrated in BM is much greater than the number of these variants subsequently recovered in
cfDNA at any timepoint, from as high as 14 variants from AB11 to as few as zero in AB06,
who was disqualified from longitudinal analysis for this reason (fig.6b, Table 3)
The ABECMA cohort saw a high number of cfDNA mutations relative to gDNA
mutations, including in SHM targets BTG2, BCL6, and CXCR4. However, oncogenes were
represented in this cohort, including TP53, MYC, and KRAS (fig.5b).
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Table 3: Number of BM-DSCS-confirmed cfDNA variants available to track over time
Patient

Calibration
D+0
cfDNA
cfDNA
AB_01
3
2
AB_02
5
4
AB_03
2
6
AB_04
6
2
AB_05
8
7
AB_06
2
0
AB_07
2
2
AB_08
15
7
AB_09
3
2
AB_11
14
14
AB_12
7
4
AB_13
2
1
AB_14
6
NS
AB_15
3
2
AB_16
12
NS
AB_18
11
10
AB_19
8
NS
AB_20
5
NS
NS= No sample collected

D+2
cfDNA
2
3
5
2
8
2
4
14
3
11
5
1
NS
0
NS
10
11
NS

D+7
cfDNA
4
5
3
3
8
3
3
8
2
7
0
1
NS
0
NS
11
9
NS

9.4.3 Calibration timepoint comparisons between NDMM and ABECMA cohorts
The variants identified in both cohorts differ with respect to the relative representation of
oncogenes compared to SHM targets: in particular, the greater representation of MYC,
TRAF3, and TP53 mutations in the ABECMA cohort illustrates this difference, while both
cohorts still have high representation of SHM targets such as BTG2 and BCL6 (fig.5a and
5b). The ABECMA cohort has more DSCS-confirmed variants detected in bone marrow at
the calibration timepoint (though the relationship is not statistically significant, p >0.05,
fig.5c), and more of these variants detected using SSCS enumeration in cfDNA (p <0.05, fig.
5d). The VAF of DSCS-calibrated bone marrow variants is much higher in the PA19 cohort
than in the Abecma cohort (p<0.01, fig.5e), but there is no significant difference between the
VAF of those variants enumerated in cfDNA (fig.5f).
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9.4.4 Longitudinal and outcome analysis of ABECMA patients
Due to the recency of CAR-T infusions and median overall survival, long-term
outcomes cannot be evaluated. Instead, the major outcome evaluated here is Day 30 IMWG
response, dichotomized as Complete Response (CR) or better (stringent Complete Response,
sCR); and worse (Very Good Partial Response, VGPR; Partial Response, PR; Stable Disease,
SD; and Progressive Disease, PD)[20]. In addition, as the median overall survival was
reached, analysis on the basis of survival is included here.

Table 4: VAF and VFC for all patients

Patient
Identifier

Day 0
VAF

Day 2
VAF

Day 7
VAF

AB01
AB02
AB03
AB04
AB05

0.21323
0.08248
0.00279
0.00183
0.00308

0.22192
0.11388
0.00531
0.00088
0.01267

0.11577
0.06229
0.00156
0.00168
0.00798

VAF
Fold
Change
(VFC),
D+2,
D+0
1.041
1.381
1.900
0.479
4.122

AB06

FTIC

0.00012

0.00043

NE

AB07
AB08
AB09

0.00072
0.01848
0.24753
NS-QC
(BM
failed
QC)

0.00049
0.00812
0.12196

0.00087
0.01436
0.01667

NE

NE

AB10

VAF
Fold
Change
(VFC),
D+7,
D+0
0.543
0.755
0.556
0.916
2.594

Survival
(days)

D+30
IMWG
Outcome

Alive
59
140
195
Alive

SD/MR
SD/MR
VGPR
sCR
sCR

NE

59

PR

0.681
0.439
0.493

1.211
0.777
0.067

128
Alive
Alive

sCR
sCR
sCR

NE

NE

90

SD/MR

N/A

sCR

AB11

0.03554

0.05377

0.10480

1.513

2.949

14, death
due to
CAR-T
toxicity

AB12

0.21306

0.17222

NS-QC

0.808

NE

Alive
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AB13

0.00187

0.00884

0.00115

4.731

0.614

42, death
not MMrelated

AB14

No
infusion,
deceased

N/A

N/A

N/A

N/A

Unknown

N/A

FTIC, 0

FTIC,
0

0

0

28

PD

AB15

0.00054

SD/MR

AB16

No
infusion,
deceased

N/A

N/A

N/A

N/A

Unknown

N/A

AB18

0.02815

0.06998

0.15016

2.146

4.111

Alive

CR

AB19

NS

0.09732

0.12312

NE

NE

Alive

VGPR

FTIC= Failed to identify calibration BM variants
NS-QC= No sample, sequencing QC failed
NS= no sample provided
NE= not evaluable
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Figure 7: Variant fold change for selected patients A) Variant fold change (VFC) for patient
AB01, who had marginal response at D+30. B) VFC for patient AB05, who had a stringent
complete response at D+30. C) VFC for patient AB08, who had a stringent complete
response at D+30. D) VFC for patient AB09, who had a stringent complete response at
D+30. E) VFC for patient AB11, who experienced fatal complications after infusion and died
at D+14. F) cfDNA yields per mL of plasma from AB11, who experienced a major spike in
cfDNA shedding after infusion. G) VFC for all patients, color-coded by their clinical
response at D+30.
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9.4.5 AB01, initial SD/MR improving to VGPR by 6 months
Patient AB01 received their infusion in August 2021 and had stable disease (SD/MR)
at the D+30 follow-up but was MRD-. By the 3 month follow-up, their assessment improved
to a partial response (PR), and by 6 months, to a VGPR with durable survival (still alive at
last update). Their VFC rose slightly to 1.041 (median VFC) at D+2 but decreased to 0.543
by D+7 (fig.7a).

9.4.6 AB05, long-term sCR, elevated VFC
Patient AB05 received their infusion in September 2021 and achieved sCR and MRDby D+30 follow-up, which was sustained out to 6 months after infusion with durable
response. Their VFC rose to 4.122 at D+2 and declined slightly to 2.594 by D+7 (fig.7b).

9.4.7 AB08, long-term sCR, depressed VFC
Patient AB08, who had previously received another anti-BCMA therapy, received
their infusion in September 2021 and achieved sCR and MRD-by D+30 follow-up, which
was sustained out to 6 months after infusion with durable response. Their VFC declined to
0.439 at D+2 before rising slightly to 0.777 by D+7 (fig.7d).

9.4.8 AB09, long-term sCR, depressed VFC
Patient AB09 received their infusion in September 2021 and achieved sCR and MRDby D+30 follow-up, which was sustained to 6 months after infusion. Their VFC declined to
0.493 at D+2 and 0.067 at D+7 (fig.7d).
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9.4.9 AB11, CRS/HLH/Infection, steadily increasing VFC
Patient AB11 received their infusion in September 2021 and experienced major
toxicity, autoimmune complications, and infection. They died on D+14 after infusion. The
VFC was 1.513 at D+2 and 2.949 at D+7 (fig.7e)
AB11 was unique among their peers in that cfDNA shedding was substantially higher
than in the remainder of the cohort, potentially due to the side effects of the CAR-T therapy
and associated conditions (fig.7f); however, the VFC steadily rises over time.

9.4.10 Summary of VFC across patients
There is no statistically significant difference between the D+2 VFC in those patients
achieving CR or better as opposed to those who did not (Mann-Whitney test, P=0.1490), nor
was there a difference in the D+7 VFC between these groups (Mann-Whitney test, P=0.3290)
(fig.8b).
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9.4.11 Correspondence between VAF change and outcomes

Figure 8: Outcome and survival comparisons with VFC A) Waterfall plot of VFC at D+2,
coded by clinical response at D+30. B) VFC for each patient, coded by clinical response at
D+30. C) Survival of patients receiving Ide-cel in this cohort. D) Survival of patients in the
ABECMA cohort, divided by VFC at D+2.

Evaluable patients were divided into groups based on their VFC at D+2 was greater
than or equal to the median VFC or not. Of those patients with ≥Median VFC (n=7), one
experienced a D+30 CR, one SCR, one VGPR, three SD/MR, and one patient, AB11, was
deceased. Of those with <Median VFC (n=6), five experienced sCR and one experienced
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progressive disease (fig.8a). There was no statistically significant difference in the outcomes
of these two groups (Fisher’s exact test, P=0.1026).
As described above, two patients (AB11 and AB13) are censored from survival
analysis due to their deaths not being related to MM. The difference in survival between
those patients with ≥Median VFC and <Median VFC is not statistically significant (Log-rank
P=0.1574, fig.8d).
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10 Discussion
10.1 Design and performance of M5Seq
Revision of the MM_M4 panel to M5Seq was performed in order to port the new
panel to hg38 for manufacture by Twinstrand Biosciences. In working with specialists at
Twinstrand, several regions of the panel were identified which had a high number of offtarget BLAST hits, a high ΔG° of folding, or highly repetitive sequences. Designing probes
for this region proved problematic because off-target capture was likely to occur and variants
were likely to be spurious true variants, i.e. irrelevant to the tumor. Many of these regions
were removed, including several IGH, IGL, and IGK loci which may have revealed a relevant
tumor clonotype.
Revision of the MM_M4 hybrid capture panel led to a meaningful decrease in
applicability in silico: while the MM_M4 panel had 99.41% applicability, and 90% of tumors
had at least 10 variants detected, the M5Seq panel had 97% applicability and 71% of tumors
had at least 10 variants detected. However, relative decrease in off-target sequencing,
combined with higher on-target rates resulting from the Twinstrand capture protocol, may
have mitigated this problem, though this has not been experimentally validated. Analysis of
the NDMM samples indicates that true mutation coverage of the panel is much higher
(fig.4a), and every patient in both cohorts shown here had more than the in silico mode of 6
variants identified in their bone marrow and called by DSCS. This may be due to increased
sequencing depth used for the tumors investigated here compared to the WGS-identified
variants in the CoMMpass databse and the higher specificity of sequencing resulting from
hybrid capture.
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10.1.1 Trade-offs of sequencing depth and breadth
There is an inherent trade-off between sequencing breadth and depth: the tumors in
the CoMMpass database were sequenced using broad whole genome sequencing or exome
sequencing (WES) with sequencing depth one to two orders of magnitude less than the
sequencing depth employed in this study. The resulting difference in sensitivity means that in
a library with, for example, 200x mean depth should not expect to reliably see rare variants
with oVAF < 5x10-3, whereas in spike-in libraries with 25,000x mean depth, variants with
oVAF < 5x10-5 were observed. While exome sequencing should identify variants in a larger
selection of the genome, by tiling specifically for regions with high frequency of variants, the
CaPP-Seq method preserves as many of the identified variants as possible while ignoring
regions where variants are infrequent and likely immaterial to the disease. The additional
benefit of the additional depth used in targeted sequencing is the ability to detect changes of
VAF over several orders of magnitude, whereas WES is not able to detect low levels of
disease with the same amount of sequencing, as observed by Manier et al[45], who use WES
in active disease only.

10.1.2 Analytical sensitivity
Sensitivity of a sequencing assay is a function of multiple factors, including
sequencing depth, library complexity, and sequencing error rates. Average sequencing depth
is the number of reads covering a certain location in the genome and corresponds to the
divisor in a calculation of the frequency of a variant, i.e. number of total reads confirming a
variant divided by total depth at that variant. The probability of detecting a variant is given
by the Poisson distribution, which predicts the likelihood of detecting multiple discrete
events. If the true VAF of a variant is greater than the inverse of sequencing depth, then the
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probability of detecting the variant is 1; however, if the true VAF of a variant is less than the
sequencing depth, then the probability of detecting it is less than 1 and again predicted using
a Poisson distribution. However, the probability of detecting each variant is additive, so
while the probability of detecting one variant might be very low, if multiple variants are
present, the probability of detecting any variant (and therefore disease burden) is determined
by the frequency of each variant and the number of total variants. Therefore, at low levels of
disease burden, the detection of some variants is certain, but the total number of variants
detected decreases substantially, and the detection a given variant is stochastic. By
sequencing relatively few loci at great depth, we demonstrated an ability to detect variants
using SSCS at an observed VAF of 5x10-5, thus increasing the probability of detecting
variants which are present at lower frequency than the depth of sequencing in other
experiments. As a result, we detect variants at EAF<10-5 but no less than oVAF=5x10-5, and
these variants are not consistent from dilution series to dilution series, though all are detected
in the calibration sample. In order to detect variants at greater depth consistently, sequencing
depth would need to be increased, and this would likely also improve linearity of the assay as
the oVAF of a low-frequency variant approaches that of its EAF.
Common to all experiments is sequencer and polymerase error: while Illumina
sequencers have error rates on the order of 0.01% (10-4)[108], sequencing in excess of 3x108
bases per sample, as was the case with each spike-in library, means that 104 sequencing
errors will be generated. Additional variant reads will be generated due to polymerase error
during the PCR required for library preparation. The polymerase error rate for the enzyme
used in all the experiments reported here is on the order of 10-5-10-6 bases incorporated[109],
adding further sources of error in the library prep. As demonstrated by the SSCS vs DSCS
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comparisons in the spike-ins, NDMM, and ABECMA pre-treatment comparisons, PCR and
sequencing errors are largely mitigated by DSCS calibration without affecting sensitivity.
Another major factor affecting analytical sensitivity is library complexity, defined as
the number of unique molecules in a sequencing library. Library complexity is the result of
two factors: total DNA input and conversion rate, or the percentage of molecules successfully
converted to library. Using the Twinstrand library preparation protocol, library conversion is
10% for sonicated genomic DNA as used in spike-ins and bone marrow samples, and 30%
for cfDNA; as such, more sequencing reads are required to sequence cfDNA samples to the
same depth as sonicated gDNA samples. In turn, the best way to increase library complexity
is to increase sample DNA input whenever possible. The samples sequenced here were
limited to a maximum of 250ng sonicated gDNA, 100ng cfDNA for pre-treatment samples,
and 50ng for longitudinal samples; however, this limit was infrequently achieved, especially
in NDMM pre-treatment samples when disease burden and cfDNA shedding was low. In
instances where cfDNA shedding is high, while libraries can be made from >1500ng DNA,
sequencing costs to achieve necessary depth rapidly cause sequencing to become
uneconomical. In sum, the limiting factor of the sensitivity of the assay is DNA input, as
demonstrated by the spike-in experiments: by using 1500ng DNA input, we sequenced
500,000 haploid genome equivalents to an average depth of ~20,000x. In contrast, 100ng
cfDNA input is equivalent to 33,000 haploid genome equivalents at 10,000x depth, and lowinput samples of 30ng are equivalent to 10,000 haploid genome equivalents at 5,000x depth.
Here, we sought to strike a balance between economy of sequencing, sequencing depth, and
library complexity.
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As shown in figure 3c and 3d, calling variants using DSCS in all spike-in libraries is
insufficient to detect low frequency variants at less than 10-4. This is due to the
considerations listed above, chiefly that when using DSCS variant calling, a failure to
reconcile paired reverse complement strands leads to a loss of average variant depth and
resulting loss of sensitivity (fig.3e). However, this is rescued by calling variants in the
calibration sample in duplex to mitigate sequencing error, thus contributing confidence to
variant calls, and then only requiring single strand support for the variant in successive
samples, as shown in figures 3a and 3b. Due to the increased variant depth when using SSCS,
variants are called at VAF as low as 5x10-5. Analysis when using SSCS exclusively, even for
calibration, does lead to a great deal of expected genomic noise which confounds data
analysis.
As shown in figures 3a and 3b, linearity on a logarithmic scale is lost at an EAF of
10-4 for both the U266 and H929 spike-ins. Loss of linearity indicates that a variant’s OAF, if
quantitated at <10-4 indicates that the true VAF is <10-4 but cannot be accurately quantified.
This is similar to a common result in ASO-qPCR MRD assays, which may return a result of
“Positive, Non-Quantifiable” (PNQ). A PNQ result is still useful for detecting low-level
disease and molecular response.
Due to the combination of loss of linearity at 10-4, limit of sensitivity of 5x10-5, and
practical considerations such as library complexity, the limit of sensitivity of the assay in
clinical practice is likely less than demonstrated here, and therefore may not accurately
measure MRD at the limit of sensitivity demonstrated by clonoSEQ or MFC-based assays.
However, this analysis has specifically excluded plasma samples that are contemporaneous
with MRD measurements: in particular, at D+28/D+30 from CAR-T infusion for the
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ABECMA cohort. As the majority of patients were MRD- at D+30 (Table #1), it may be
informative to interrogate these samples for VFC at the D+30 timepoint, as was done by
Deng et al[118], especially since several MRD- patients relapsed after D+30. However,
given the small sample size, it is possible that this cohort would not be informative. More
investigation, including a mature cohort with multiple long-term survivors, is needed to
investigate the true utility of this assay for MRD detection purposes.

10.2 Applications
10.2.1 Variant filtering in the absence of a matched normal sample
Like any NGS assay, hybrid capture assays are challenged by the need to ascertain
what is a germline variant and what is a tumor-derived variant. The CaPP-Seq method and its
iterations typically requires the use of a matched normal sample for every patient as a part of
the calibration step in order to remove germline variants: the normal sample, usually PBMC,
is sequenced at less depth than the clinical sample in order to identify obvious germline
variants. While this is the standard practice for CaPP-Seq assays, it has two weaknesses: first,
removing only biallelic and heterozygous variants may leave behind low-frequency germline
variants and off-target non-tumor SHM variants, which when included in VAF calculations
may skew VAF calculations as the tumor-derived VAF changes over time; alternately,
inclusion of low-frequency variants in blacklists may cause true tumor variants to be
blacklisted. Another alternative which minimizes sequencing cost is to perform low-pass
whole genome sequencing (lpWGS) in order to estimate tumor purity, and therefore
establishing a VAF threshold based on the tumor purity.
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These experiments did not use a matched normal sample, so analysis is, strictly
speaking, ignorant of germline variants. The stringent filtering strategy used here involved
using multiple compendia of population-level mutational databases to eliminate common
variants and repetitive elements, and the average VAF in patient samples is reflective of this:
the average VAF for each patient is >0.1 (table 3). However, it is likely that several true
tumor-derived variants were lost in this filtering step, potentially negatively affecting the
utility of this assay by blunting its sensitivity to detect VAF changes.
This is particularly apparent when comparing the DSCS and SSCS consensus pretreatment comparisons of both cohorts, as there is not a substantive increase in concordant
variants by using SSCS in many cases, and in fact, the median concordance decreases (29%
in DSCS vs 14% with SSCS in the ABECMA cohort), and slightly fewer variants are called
in the SSCS data than in the DSCS data (median 45.5 vs 38.5). This suggests that the plan of
tracking SSCS-confirmed variants calibrated in DSCS BM may not achieve the increased
sensitivity and applicability, as approximated by number of SSCS-supported, DSCS-BM
calibrated variants. However, this problem may be attributed to the filtering step, as analyses
which do not use the dbSNP and repeatMasker annotations, but which do use PAF and the
PoN, do not suffer from this issue. For M5Seq to be incorporated into a clinical setting, this
process will need major refinement. Alternatives to the dbSNP and repeatMasker steps
include using a matched normal sample with a conservative VAF cutoff (e.g., blacklist
anything with VAF>0.4), or limiting analysis in the absence of a normal sample to variants
below a VAF “cap” above which threshold variants are not included in longitudinal analysis.
This may be done directly through analysis of the pre-treatment BM captured library, or
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indirectly via lpWGS and tumor fraction estimation of the pre-capture library for the same
sample.

10.2.2 Inter-sample concordance and implications of low concordance
Concordance between the pre-treatment NDMM sample compartments, using DSCS,
was generally fair. All tumors presented more variants than the average number of variants
detected in the in silico validation cohort (11.89), but the median concordance was <25%,
and the resulting low number of concordant variants decreases the probability of detecting
low disease burden. For instance, at a given VAF, MM0018 and MM0012 have a lower
probability of detecting variants than do MM0015 and MM0031 due to the difference in
concordant variants. Moreover, the inability to detect concordant variants in the cfDNA of
two patients (MM0014 and MM0019) using DSCS indicates the limitations of this approach,
as no mutations could be followed longitudinally with high confidence in these patients.
However, the benefit of switching to SSCS confirmation of calibrated variants is not
clear in this cohort as was anticipated. The SSCS data indicate a preponderance of variants in
all samples, but concordance does not improve overall, and while MM0018 is rescued (5
concordant variants, as opposed to 0 in the DSCS comparison), MM0014 still has no
concordant variants and, uniquely, MM0018 loses their concordance.
Taken together, this approach demonstrates the limitations of this approach when
stringently filtering variants, as concordance is low and likely true tumor variants are
blacklisted from analysis.
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10.2.3 Challenges of subsampling in M5Seq
cfDNA sequencing is an attempt to reproduce the local features of a primary tumor in a
global compartment- as such, a subsample is being taken which may not perfectly represent
the primary tumor, as we and others show. If we assume, for instance, that an average plasma
sample from a 10mL blood tube contains 50ng of DNA (at 10ng cfDNA/mL plasma), then
we are sampling roughly 7,600 haploid genome equivalents from a total of nearly 3.8 million
genome equivalents, a proportion of 1/500. Variant molecules which are not present at a
frequency of greater than 3/500 (due to the “rule of three” in Poisson sampling) have a
chance of being sampled of <1. From there, the molecules must be extracted from the plasma
and turned into library molecules, which has efficiency of <50%. From there, it must be
captured and sequenced. In this light, increased cfDNA input into library construction is the
factor which has the greatest impact on the ability to detect rare variants, and this may come
from higher cfDNA burden in plasma or from multiple blood tubes. While subsampling is
unavoidable, hybrid capture maximizes the probability of detecting tumor-derived molecules
if they make it through these multiple subsampling steps.

10.3 Applications in CAR-T therapy
10.3.1 Inter-compartment concordance in CAR-T patients has not been studied
Consistent with the analysis of NDMM samples, concordance between pre-treatment
cfDNA and bone marrow samples is low, with fewer than 30% of variants identified in both
pre-treatment compartments using DSCS. This is an improvement compared to PA19
samples, and is likely due to the greater mutational burden. While more variants are called,
on average, in the ABECMA cohort, the lack of concordance is consistent with the PA19
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samples. Unlike the PA19 samples, however, is the reliability of the SSCS data.
Nevertheless, concordance actually decreases overall, and fewer variants are called overall.
This further challenges the idea that SSCS confirmation of DSCS-calibrated variants
increases sensitivity. While there is still high confidence that the concordant variants called
are true variants which can be followed over time, it is again likely that true tumor variants
are being blacklisted in this analysis.

10.3.2 VFC may predict outcomes within 2/7 days
These experiments identified trends between VFC at D+2 and IMWG response at
D+30; however, these trends did not rise to the level of statistical significance. Indeed, while
the majority of CR patients had a decrease in VFC by D+2, this trend was not stastically
significant. Concerningly, in multiple instances patients (AB05 and AB18) achieved sCR
and, in the case of AB05 (AB18 only received infusion in January 2022), experienced
prolonged survival despite an elevated VCF at both D+2 and D+7. These data indicate that
M5Seq alone cannot prognosticate survival given the limitations of this study; however,
additional experimentation may be warranted to demonstrate the efficacy of M5Seq. Patients
AB05 and AB18 demonstrate a paradoxical “spike” in VAF at D+2, which has been
documented in literature previously, though not in the context of CAR-T therapy- to our
knowledge, this represents the first observation of a ctDNA spike in CAR-T therapy. In
myeloma, the spike has been observed 3-5 days following standard chemotherapy, but
investigators found it to be inconsistent when using captured sequencing[123]. The presence
of the spike has been suggested [124] to be demonstrative of sustained anti-tumor activity of
the therapeutic agent over the days following treatment, but the fact that the spike is only
present in a minority of cases suggests that this is not the whole story. Moreover, in the
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context of short-term response, this needs to be adequately controlled for and understood
when assessing short term response.

10.3.3 Clinical application of M5Seq
Here, we demonstrated that M5Seq has sufficient analytical sensitivity and
applicability to detect low-frequency variants but may lack the prognostic power necessary to
accurately predict response to CAR-T therapy through the use of ctDNA, hybrid capture, and
massively parallel sequencing. However, the small sample size available may justify further
study to see whether statistical significance is hindered by the number of patients. While
assays exist for MM which use liquid biopsies, and/or hybrid capture and massively parallel
sequencing, these assays are primarily designed for detection of MRD, and no such assays
are designed for use in a dynamic treatment environment.
Given sensitivity, specificity, applicability, and qualified ability of M5Seq to
prognosticate outcomes, M5Seq may provide some clinical utility to investigators in
assessing CAR-T response in MM. Given the recent approval and improvements in outcomes
in cilta-cel patients compared to ide-cel patients, M5Seq may identify changes in molecular
response between the two treatment groups, which in turn may establish the superiority of
one therapy over another. In addition, the efficacy of CAR-T therapy advocates for its use in
treatment settings less advanced than relapsed/refractory MM, and molecular response may
play a greater role in predicting outcomes in that treatment setting.

10.4 Future Directions
While ctDNA is a promising avenue for investigating response to MM therapy in a
dynamic range, the biological reality of lymphoid malignancies is complex and may be better
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served using a multimodal approach. Deng et al integrated molecular response data with
single-cell transcriptomic and immunologic features of axicabtagene ciloleucel (axi-cel)
infusion products, finding that the molecular response corresponded to the fraction of
exhausted CD8+ T cells in the infusion product, thus suggesting that the efficacy of axi-cel
therapy can be influenced by the health of the T-cell repertoire at apheresis, and limited
tumor biopsies supported these results. Similarly, the data reported here are one element of a
larger project investigating responses to ide-cel, both in bone marrow and in cfDNA. Work is
underway to assess single-cell transcriptomic and immunologic features of the primary
tumors sequenced here in order to similarly integrate these data and better understand how
and why ide-cel fails.
Another promising avenue for this project is the integration of low-pass whole
genome sequencing (lpWGS). lpWGS identifies high-level chromosomal defects such as
deletions and hyperdiploidies at low cost due to the low sequencing coverage required, and
the magnitude of these defects is indicative of disease burden in MM[45]. Moreover, our
group demonstrated recently that in DLBCL, lpWGS carries prognostic value and is able to
stratify patients on risk of relapse after axi-cel based on pre-infusion cfDNA samples[93].
Sequencing pre-infusion cfDNA in this manner may further the idea that cfDNA is
prognostic for CAR-T response. In addition, the lpWGS results from bone marrow can be
used to estimate tumor purity, which can then be used to determine a VAF cutoff for filtering
non-tumor variants when applying M5Seq to the same tumors. Using the same protocols used
here, lpWGS libraries may be generated without any extra work, as a diluted aliquot of
library taken for QC before capture contains sufficient DNA to perform lpWGS.
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It is notable that the median OS in this cohort underachieves when compared to the
KarMMa trial cohorts which engendered FDA approval of ide-cel (fig.8c)[14, 15]. This
cohort may have failed to perfectly represent patients receiving ide-cel, and as new patients
continue to receive ide-cel, continuous evaluation of survival and molecular response may
display improved survival and better prognostic ability. In short, the use of M5Seq in broader
patient cohorts may reveal greater utility. Furthermore, promising results from the
CARTITUDE trials and recent FDA approval of anti-BCMA ciltacabtagene autoleucel (ciltacel) provide a treatment which may be studied in comparison and competition with ide-cel,
and utilizing M5Seq to assess molecular response can contribute to comparative studies of
the two myeloma CAR-T products.
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